World's Best Scientists 2026 revealed!
Juan José Lasarte

Juan José Lasarte

D-Index & Metrics

Immunology

D-Index
60
Citations
12289
World Ranking
3340
National Ranking
37

Juan José Lasarte publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Juan José Lasarte sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 241 publications — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Juan José Lasarte D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Juan José Lasarte sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 60 D-Index — 33rd percentile

33% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Juan José Lasarte is affiliated with the University of Navarra in Spain. Their research spans multiple fields within biomedical science, focusing primarily on medicine, immunology and microbiology, and biochemistry, genetics and molecular biology. Their work explores key subfields such as immunology, oncology, molecular biology, hematology, and infectious diseases.

The scientist's research concentrates on several main topics including CAR-T cell therapy research, immunotherapy and immune responses, immune cell function and interaction, cancer immunotherapy and biomarkers, biosimilars and bioanalytical methods, viral infectious diseases and gene expression in insects, and multiple myeloma research and treatments.

Juan José Lasarte has published extensively in a number of scientific journals. The most frequent publication venues include:

  • Blood
  • Journal for ImmunoTherapy of Cancer
  • Frontiers in Immunology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Lymphoma Myeloma & Leukemia

Frequent co-authors collaborating with Juan José Lasarte include:

  • Felipe Prósper
  • Teresa Lozano
  • Juan R. Rodriguez-Madoz
  • Noëlia Casares
  • Susana Inogès

Some of the recent papers associated with their research are:

  • "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death," 2020, Journal for ImmunoTherapy of Cancer
  • "Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade," 2020, Nature Cancer
  • "CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome," 2022, Science Advances
  • "SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation," 2021, Journal for ImmunoTherapy of Cancer
  • "The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?" 2021, Cancers

Best Publications

  • A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

    Bruno Sangro;Carlos Gomez-Martin;Manuel de la Mata;Mercedes Iñarrairaegui

  • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Lorenzo Galluzzi;Ilio Vitale;Sarah Warren;Sandy Adjemian

  • Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.

    Yuting Ma;Laetitia Aymeric;Clara Locher;Stephen R Mattarollo

  • Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy

    Yuting Ma;Yuting Ma;Laetitia Aymeric;Laetitia Aymeric;Clara Locher;Clara Locher;Stephen R. Mattarollo

  • Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.

    Leticia Corrales;Daniel Ajona;Stavros Rafail;Juan J. Lasarte

  • CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination

    Noelia Casares;Laura Arribillaga;Pablo Sarobe;Javier Dotor

  • Transmission of hepatitis C virus infection to tree shrews.

    Zhi-Chun Xie;Jose-Ignacio Riezu-Boj;Juan-Jose Lasarte;Javier Guillen

  • A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis

    Daniel Ajona;Sergio Ortiz-Espinosa;Haritz Moreno;Teresa Lozano

  • Abnormal Priming of CD4+ T Cells by Dendritic Cells Expressing Hepatitis C Virus Core and E1 Proteins

    Pablo Sarobe;Juan José Lasarte;Noelia Casares;Ascensión López-Díaz de Cerio

  • Topical Application of a Peptide Inhibitor of Transforming Growth Factor-β1 Ameliorates Bleomycin-Induced Skin Fibrosis

    Begoña Santiago;Irene Gutierrez-Cañas;Javier Dotor;Guillermo Palao

  • Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses

    Pablo Sarobe;Juan José Lasarte;Aintzane Zabaleta;Laura Arribillaga

  • Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.

    Cristina Segovia;Edurne San José-Enériz;Ester Munera-Maravilla;Mónica Martínez-Fernández

  • Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.

    Edurne San José-Enériz;Xabier Agirre;Obdulia Rabal;Amaia Vilas-Zornoza

  • Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.

    Sarita M. Fernandez-Poma;Diego Salas-Benito;Teresa Lozano;Noelia Casares

  • A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury.

    Ignacio-José Ezquerro;Juan-José Lasarte;Javier Dotor;Inma Castilla-Cortázar

  • Upregulation of Indoleamine 2,3-Dioxygenase in Hepatitis C Virus Infection

    Esther Larrea;José I. Riezu-Boj;Lucía Gil-Guerrero;Noelia Casares

  • A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats.

    Nerea Hermida;Begoña López;Arantxa González;Javier Dotor

  • A Peptide Inhibitor of FOXP3 Impairs Regulatory T Cell Activity and Improves Vaccine Efficacy in Mice

    Noelia Casares;Francesc Rudilla;Laura Arribillaga;Diana Llopiz

  • Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model

    Diana Llopiz;Marta Ruiz;Lorea Villanueva;Tamara Iglesias

  • The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses In Vivo

    Juan J. Lasarte;Noelia Casares;Marta Gorraiz;Sandra Hervás-Stubbs;Sandra Hervás-Stubbs

  • Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Daniel Ajona;Sergio Ortiz-Espinosa;Teresa Lozano;Francisco Exposito

  • Poly(Anhydride) Nanoparticles Act as Active Th1 Adjuvants through Toll-Like Receptor Exploitation

    I. Tamayo;J. M. Irache;C. Mansilla;J. Ochoa-Repáraz

Frequent Co-Authors

Jesús Prieto
Jesús Prieto University of Navarra
Sandra Hervas-Stubbs
Sandra Hervas-Stubbs University of Navarra
Ignacio Melero
Ignacio Melero University of Oxford
Bruno Sangro
Bruno Sangro University of Navarra
Ruben Pio
Ruben Pio University of Navarra
Felipe Prosper
Felipe Prosper University of Navarra
Jonathan L. Heeney
Jonathan L. Heeney University of Cambridge
François Ghiringhelli
François Ghiringhelli Centre Georges François Leclerc
Luis M. Montuenga
Luis M. Montuenga University of Navarra

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often involves interdisciplinary education and specialized certifications that enhance expertise and job prospects. For those interested in advancing clinical skills, obtaining an acute care certification for FNP can open doors to more complex patient care roles, especially in acute and critical care settings.

Nursing professionals looking to expedite their education may consider accelerated nurse practitioner programs. These online programs allow learners to fast-track their studies, balancing flexibility with rigorous coursework ideal for ambitious students who want to enter the workforce quickly.

For those without prior nursing experience, there are comprehensive online nursing programs for non nurses that provide foundational knowledge alongside advanced nursing principles, enabling a smooth transition into healthcare roles related to immunology and patient care.

Additionally, accelerated tracks like ABSN programs with high acceptance rates offer accessible entry points for motivated individuals seeking to quickly earn their Bachelor of Science in Nursing, which can be pivotal for careers involving clinical immunology and research.

Best Scientists Citing Juan José Lasarte

Trending Scientists

Recently Published Articles